Devonian Health Group (CVE:GSD) Trading Up 12.2% – Here’s What Happened

Devonian Health Group Inc. (CVE:GSD)’s share price traded up 12.2% during trading on Thursday . The stock traded as high as C$13.75 and last traded at C$13.75. 1,000 shares traded hands during mid-day trading, a decline of 35% from the average session volume of 1,536 shares. The stock had previously closed at C$12.25.

Devonian Health Group Stock Down 12.7%

The firm has a 50-day moving average of C$12.01 and a two-hundred day moving average of C$11.35. The stock has a market capitalization of C$33.19 million, a price-to-earnings ratio of -4.35 and a beta of 1.38. The company has a quick ratio of 7.82, a current ratio of 1.07 and a debt-to-equity ratio of 16.36.

About Devonian Health Group

Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.